2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. CA VB Isoform

CA VB

CA VB (CA5B) is a mitochondrial carbonic anhydrase isoform that catalyzes CO2 hydration to support bicarbonate-dependent metabolism[1][2]. Mechanistically, CA VB contributes to Krebs cycle anaplerosis by supporting mitochondrial oxaloacetate synthesis in pancreatic β cells[3]. In mouse islets and Min6 β cells, thiazides inhibited glucose- and sulfonylurea-stimulated insulin secretion through CA5B inhibition[3]. CA5B knockout mice resisted thiazide-induced glucose intolerance, which identifies CA VB as the functional thiazide-sensitive isoform in this β-cell model[3]. Compared with CA VA, CA VB shows broader tissue distribution, whereas CA VA is most highly expressed in liver and has a predominant role in ammonia detoxification[2]. This isoform distinction matters because CA5A sequencing identified disease-causing variants in early-onset metabolic crisis, while the same cohort found none in CA5B[4]. CA VB also differs pharmacologically from CA VA, because human CA VB shows greater sensitivity to anion inhibitors and a distinct bicarbonate inhibition profile[5]. For experimental applications, CA VA/VB inhibitors reduced paclitaxel-induced neuropathic pain and improved mitochondrial dysfunction in mice[6]. In cerebrovascular models, CA VB inhibition or deletion reduced amyloid- and tau-linked endothelial dysfunction, BBB disruption, and inflammatory activation[7].

References:

CA VB Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-109056
    Elsulfavirine
    		Inhibitor 99.90%
    Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer.
  • HY-109056A
    Elsulfavirine sodium
    		Inhibitor
    Elsulfavirine sodium (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer.